Response to viscosupplementation with HAppyCross in hip OA: Discover the results in our published article

Published by admin on

BMC - Musculoskeletal Disorders

Predictors of response to viscosupplementation in patients with hip osteoarthritis: results of a prospective, observational, multicentre, open-label, pilot study. Eymard et al. BMC Musculoskeletal Disorders (2017) 18:3. DOI 10.1186/s12891-016-1359-2.

STUDY DESIGN

  • Prospective, observational, multicentre, open-label study:
    • 100 hip OA
    • 59 men /41 women; mean age 62  (36-87)
    • BMI 25,4 (17,9-41,8)
    • 1 injection of HANOX-M-XL(HAppyCross®) under US or fluoroscopy
    • Population ITT: 100, PP: 90
  • Outcome measures:
    • WOMAC pain and function scores as well as patient global assessment (PGA) were assessed at baseline and day 90
    • Improvement, satisfaction and efficacy were self-assessed at day 90
  • Predictors of response:
    • Clinical
    • Radiodiological
    • MRI

RESULTS

  • All outcome measures improved significantly between D0 and D90 (P<0.0001).
  • 80% of patients considered them as « improved ».
  • 48% were RESPONDERS (improvement >50%)

.Previcox results 1

Results Previcox 2

Results Previcox 3

.

 

Read Full Text

 

HAppyCross